According to the World Health Organization, around 10.8 million people developed tuberculosis globally in 2024, while approximately 1.25 million people died from the disease, making it one of the world’s deadliest infectious illnesses.
Globally, an estimated 39.9 million people are living with HIV, creating continuous demand for viral load monitoring, CD4 testing, and diagnostic reagents throughout a patient’s lifetime.
Seasonal influenza affects nearly 1 billion people every year, including 3–5 million severe cases and up to 650,000 respiratory deaths annually.
Malaria continues to impact healthcare systems, with around 263 million reported cases and nearly 597,000 deaths worldwide in 2023, increasing the need for rapid diagnostic tests across developing countries.
Dengue has also reached record levels, with the World Health Organization reporting more than 14 million cases globally in 2024, more than double the previous year’s total.
Healthcare spending is following this trend.
Global in-vitro diagnostic testing now accounts for only a small percentage of overall healthcare expenditure but influences an estimated 60–70% of clinical decisions, making diagnostic reagents one of the highest-value components in modern medicine despite representing a relatively small portion of hospital budgets.
More hospitals are also adopting molecular diagnostics.
Real-time PCR remains the gold standard for detecting infectious diseases because of its high sensitivity, while multiplex molecular panels can now detect 20 or more respiratory pathogens from a single patient sample, significantly reducing diagnosis time.
Global Infectious Disease Statistics
The rising burden of infectious diseases continues to drive sustained demand for diagnostic reagents across hospitals, laboratories, and public health agencies.
| Disease / Indicator | Latest Statistics |
|---|---|
| Tuberculosis cases worldwide | 10.8 million people |
| Tuberculosis deaths | 1.25 million annually |
| People living with HIV | 39.9 million |
| New HIV infections annually | 1.3 million |
| Seasonal influenza infections | 1 billion cases/year |
| Severe influenza cases | 3–5 million annually |
| Influenza-related respiratory deaths | 290,000–650,000/year |
| Malaria cases | 263 million |
| Malaria deaths | 597,000 |
| Global dengue cases (2024) | 14+ million |
| Clinical decisions influenced by laboratory diagnostics | 60–70% |
| Healthcare spending represented by IVD testing | Around 2–3% |
These numbers explain why infectious disease diagnostics remain a strategic healthcare investment rather than simply another laboratory expense.
Consumer Behavior: Healthcare Is Becoming Faster, Preventive, and Digital
Consumer expectations have changed dramatically over the past five years.
Patients no longer accept waiting several days for diagnostic results. Hospitals increasingly prioritize assays capable of delivering results within 30 minutes to 2 hours, allowing physicians to diagnose and begin treatment during the same visit.
The COVID-19 pandemic also transformed public confidence in self-testing. More than billions of rapid COVID-19 diagnostic tests were performed globally, making home-based infectious disease testing a mainstream healthcare behavior rather than an emergency solution.
Source: https://www.towardshealthcare.com/insights/diagnostic-reagents-for-infectious-diseases-market-sizing
Preventive testing has become routine across many healthcare settings. Infectious disease screening is now commonly performed before surgeries, during pregnancy, for international travel, organ transplantation, blood donation, and chronic disease management.
Healthcare has also become increasingly digital. Laboratory reports are now integrated into hospital portals, mobile applications, and telemedicine platforms, enabling physicians to review diagnostic findings remotely and accelerate treatment decisions.
Key Consumer Trends
| Healthcare Behavior | Market Impact |
|---|---|
| Same-day diagnosis preferred | Higher adoption of rapid molecular diagnostics |
| Growth in home testing | Increased demand for easy-to-use diagnostic kits |
| Preventive health checkups | More routine infectious disease screening |
| Digital health adoption | Integration with laboratory information systems |
| Rising awareness after COVID-19 | Earlier testing and faster physician consultation |
What Investors, CEOs, and Healthcare Leaders Are Watching
For executives, the most attractive feature of diagnostic reagents is not simply growing disease incidence—it is the recurring business model.
Unlike laboratory instruments that hospitals replace every several years, diagnostic reagents are consumed with every patient sample. Higher testing volumes directly translate into recurring revenue.
Healthcare infrastructure expansion is creating another major opportunity. Countries across Asia-Pacific, Latin America, the Middle East, and Africa continue investing in molecular laboratories, national surveillance programs, and decentralized diagnostic centers.
Automation is becoming another competitive differentiator. Large laboratories processing thousands of patient samples every day increasingly require reagent systems compatible with fully automated analyzers that improve workflow efficiency while reducing manual errors.
Multiplex molecular diagnostics are also reshaping laboratory economics. Modern respiratory panels can identify 20–25 pathogens from a single patient sample, reducing diagnosis time while improving laboratory productivity.
Artificial intelligence is beginning to support infectious disease diagnostics through automated result interpretation, workflow optimization, and quality assurance, helping laboratories manage rising testing volumes despite workforce shortages.
Our experts don’t just share reports; they provide customized market intelligence designed around your business needs. Get your FREE sample: https://www.towardshealthcare.com/download-sample/7022
Key Business Indicators
| Business Driver | Why It Matters |
|---|---|
| 60–70% of medical decisions depend on diagnostics | Strong long-term demand |
| Every diagnostic test requires fresh reagents | Predictable recurring revenue |
| Multiplex testing identifies 20–25 pathogens simultaneously | Lower laboratory costs and faster diagnosis |
| Rising antimicrobial resistance | Greater need for precise pathogen detection |
| Expansion of molecular laboratories | Continuous increase in reagent consumption |
| AI-enabled laboratory automation | Higher operational efficiency |
Access our exclusive, data-rich dashboard dedicated to the diagnostocs market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium